Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

R.E. van Genugten, D.H. van Raalte, M. Diamant

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Original language	English
Pages (from-to)	S26-S34
Journal	Diabetes Research and Clinical Practice
Volume	86
DOIs	https://doi.org/10.1016/S0168-8227(09)70006-3
Publication status	Published - 2009

Access to Document

@article{db69ac72c310478482debc8630492c80,

title = "Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide",

author = "{van Genugten}, R.E. and {van Raalte}, D.H. and M. Diamant",

year = "2009",

doi = "https://doi.org/10.1016/S0168-8227(09)70006-3",

language = "English",

volume = "86",

pages = "S26--S34",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

AU - van Genugten, R.E.

AU - van Raalte, D.H.

AU - Diamant, M.

PY - 2009

Y1 - 2009

U2 - https://doi.org/10.1016/S0168-8227(09)70006-3

DO - https://doi.org/10.1016/S0168-8227(09)70006-3

M3 - Article

SN - 0168-8227

VL - 86

SP - S26-S34

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

ER -